{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:38:21Z","timestamp":1774946301383,"version":"3.50.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Anti-CD20 monoclonal antibody (mAb) therapies used to treat multiple sclerosis (MS) differ in their molecular structures, epitope recognition, and mechanisms of CD20-positive (CD20+) cell lysis, which may impact clinical efficacy and tolerability and support within-class switching for patients with suboptimal response to a prior anti-CD20 mAb.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>This is a retrospective case series of 7 individuals with MS treated in private practice or at an MS clinic who switched to ublituximab from a different anti-CD20 mAb therapy due to efficacy or tolerability concerns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case descriptions<\/jats:title><jats:p>Details of each case, including clinical and\/or radiological outcomes on initial anti-CD20 mAb therapy, reasons for switching, and outcomes after starting ublituximab therapy are provided.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These cases highlight suboptimal B-cell depletion, inadequate MS disease control, and\/or tolerability concerns in people with MS who had clinical improvements or stabilization of disease following a switch from ocrelizumab or rituximab to ublituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Within-class switching from a prior anti-CD20 mAb therapy to ublituximab is feasible and may improve outcomes in some people with MS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1527102","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T10:24:29Z","timestamp":1743762269000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series"],"prefix":"10.3389","volume":"16","author":[{"given":"Regina","family":"Berkovich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Calkwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Crayton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Erwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Faissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Leekoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"B1","unstructured":"Ocrevus\n          \n          \n          \n          2024"},{"key":"B2","unstructured":"Briumvi\n          \n          \n          \n          2024"},{"key":"B3","unstructured":"Kesimpta\n          \n          \n          \n          2024"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661882","article-title":"Rituximab in multiple sclerosis: are we ready for regulatory approval","volume":"12","author":"Brancati","year":"2021","journal-title":"Front Immunol"},{"key":"B5","article-title":"OCREVUS prescribing information","year":"2024"},{"key":"B6","article-title":"KESIMPTA prescribing information","year":"2024"},{"key":"B7","article-title":"BRIUMVI prescribing information","year":"2022"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de Seze","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy301","article-title":"Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis","volume":"142","author":"von Essen","year":"2019","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108455108","article-title":"Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose","volume":"108","author":"Ferrara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/DDDT.S4378","article-title":"Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC","volume":"3","author":"Natsume","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100826","article-title":"Antibody-receptor interactions mediate antibody-dependent cellular cytotoxicity","volume":"297","author":"Sun","year":"2021","journal-title":"J Biol Chem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51911","article-title":"Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism","volume":"10","author":"Kim","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202435","article-title":"The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study","volume":"73","author":"Quartuccio","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104343","article-title":"Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity","volume":"86","author":"Robinson","year":"2022","journal-title":"EBioMedicine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06974.x","article-title":"Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA\/CD16","volume":"140","author":"de Romeuf","year":"2008","journal-title":"Br J Haematol"},{"key":"B19","article-title":"Ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody (mAb), demonstrates enhanced antibody dependent cellular cytolysis (ADCC) relative to other anti-CD20 mAbs","author":"Foley","year":"2023"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520918375","article-title":"A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis","volume":"27","author":"Fox","year":"2021","journal-title":"Mult Scler"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18158163","article-title":"CD19 cell count at baseline predicts B cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab","volume":"18","author":"Abbadessa","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103830","article-title":"Faster B-cell repletion after anti-CD20 infusion in Black patients compared to white patients with neurologic diseases","volume":"63","author":"Saidenberg","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209610","article-title":"Efficacy of ofatumumab and teriflunomide in patients with relapsing MS from racial\/ethnic minority groups: ASCLEPIOS I\/II subgroup analyses","volume":"103","author":"Williams","year":"2024","journal-title":"Neurology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.nerep.2023.100167","article-title":"Wearing-off phenomenon in multiple sclerosis patients on ofatumumab: a case series","volume":"3","author":"Labani","year":"2023","journal-title":"Neuroimmunol Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/20552173241251707","article-title":"The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis","volume":"10","author":"Marian","year":"2024","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12434-w","article-title":"The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis","volume":"271","author":"Monteiro","year":"2024","journal-title":"J Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103364","article-title":"The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis","volume":"57","author":"Toorop","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/11795735241249644","article-title":"Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: a retrospective observational study","volume":"16","author":"Friedli","year":"2024","journal-title":"J Cent Nerv Syst Dis"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1609054","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1527102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:31:22Z","timestamp":1749817882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1527102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1527102"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1527102","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2025.1609054","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"article-number":"1527102"}}